New drugs in metastatic castration-resistant prostate cancer;Nouvelles thérapeutiques du cancer de la prostate métastatique résistant à la castration

Bulletin du Cancer

Volumn 97, Issue 1, 2010, Pages 149-159

  Albiges, L ^a   Loriot, Y ^a   Gross Goupil, M ^a   De La Motte Rouge, T ^a   Blesius, A ^a   Escudier, B ^a   Massard, C ^a   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Abiraterone; Prostate cancer; Targeted therapies

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; ABIRATERONE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENOSUMAB; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; ERIBULIN; ESTRAMUSTINE; LENALIDOMIDE; MDV 3100; MK 2206; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OBLIMERSEN; PACLITAXEL; PROVENGE; THALIDOMIDE; UNCLASSIFIED DRUG; XL 147; 2 (3 AMINO 2 HYDROXYPROPYL)HEXACOSAHYDRO 3 METHOXY 26 METHYL 20,27 BIS(METHYLENE)11,15 18,21 24,28 TRIEPOXY 7,9 ETHANO 12,15 METHANO 9H,15H FURO(3,2 I)FURO(2',3' 5,6)PYRANO(4,3 B)(1,4)DIOXACYCLOPENTACOSIN 5 (4H) ONE; 2-(3-AMINO-2-HYDROXYPROPYL)HEXACOSAHYDRO-3-METHOXY-26-METHYL-20,27-BIS(METHYLENE)11,15-18,21-24,28-TRIEPOXY-7,9-ETHANO-12,15-METHANO-9H,15H-FURO(3,2-I)FURO(2',3'-5,6)PYRANO(4,3-B)(1,4)DIOXACYCLOPENTACOSIN-5-(4H)-ONE; ANDROSTANE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOTHILONE DERIVATIVE; FURAN DERIVATIVE; KETONE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PYRROLIDINE DERIVATIVE;

BONE METASTASIS; CANCER IMMUNOTHERAPY; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; ARTICLE; BONE TUMOR; DRUG ANTAGONISM; IMMUNOTHERAPY; METHODOLOGY; ORCHIECTOMY; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; CASTRATION; EPOTHILONES; FURANS; HUMANS; IMMUNOTHERAPY; KETONES; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; PYRROLIDINES; RANK LIGAND; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 75749098540     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.1023     Document Type: Article

References (71)

1. Rebillard X, Tretarre B. Epidemiology of urogenital cancers in France. Rev Prat 2007 ; 57 : 595-602.
2. Remontet L, Estève J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003 ; 51 : 3-30.
3. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008 ; 26 : 4563-71.
4. Scher HI, BTM, Higano CS. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol 2009 ; 27 : Abstr 5011.
5. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009 ; 324 : 787-90.
6. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009 ; 10 : 981-91.
7. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004 ; 91 : 718-29.
8. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000 ; 289 : 1504-8.
9. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007 ; 25 : 4431-7.
10. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009 ; 27 : 1564-71.
11. Fizazi K, Miller K. Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer. BJU Int 2009 ; 104 : 1423-5.
12. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002 ; 20 : 2171-80.
13. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003 ; 21 : 679-89.
14. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, et al. A phase III randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007 ; 110 : 1959-66.
15. James N. ZD 4054, a potent specific endothelin-A receptor antagonist, improves overall survival in pain free or midly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone mtastases. Eur J Cancer 2007 ; 5S : Abstr 3LB.
16. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupi M, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castrationresistant prostate cancer. J Clin Oncol 2009 ; 27 : 2429-35.
17. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993 ; 25 : 805-13.
18. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994 ; 31 : 33-40.
19. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998 ; 16 : 1574-81.
20. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004 ; 63 : 940-5.
21. Tu SM, Millikan RE, Mengistu B, Delpassand E, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001 ; 357 : 336-41.
22. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008 ; 14 : 6302-9.
23. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009 ; 10 : 233-9.
24. Massard C, Chauchereau A, Fizazi K. The quest for the "bony Grail" of detecting circulating tumour cells in patients with prostate cancer. Ann Oncol 2009 ; 20 : 197-9.
25. Engels FK, Sparreboom A, Mathot RA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005 ; 93 : 173-7.
26. Beardsley FS, Eigl B. A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol 2009 ; 27 : Abstr 5139.
27. Rivera E, Lee LJ, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008 ; 13 : 1207-23.
28. Small AH, Weinberg VK. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium. J Clin Oncol 2009 ; 27 : Abstr 5058.
29. Bono JD. Phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy. ASCO Genitourinary Cancers Symposium 2009 (Abstr 166).
30. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009 ; 20 : 703-8.
31. Picus J. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003 ; 22 (ASCO Annual Meeting): Abstr 1578.
32. Ning YM. A phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). ASCO Prostate Cancer Symposium 2006; Abstr 224.
33. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase II study. Eur Urol 2008 ; 54 : 1089-94.
34. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008 ; 14 : 209-14.
35. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine-kinase inhibitor for the treatment of cancer. Cancer Res 2005 ; 65 : 4389-400.
36. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine-kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007 ; 25 : 445-51.
37. Figg WD, Kruger EA, Price DK, Kim S, Dahut WD. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002 ; 20 : 183-94.
38. Figg WD, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001 ; 7 : 1888-93.
39. DahutWL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004 ; 22 : 2532-9.
40. Petrylak DP. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J Clin Oncol 2009 ; 27: Abstr 5156.
41. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007 ; 18 : 1765-73.
42. Yu EY. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. J Clin Oncol 2008 ; 26 (ASCO Annual Meeting): Abstr 5156.
43. Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting Bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense Bcl-2 oligodeoxynucleotides. Urology 1999 ; 54 : 36-46.
44. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001 ; 7 : 3920-7.
45. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormonerefractory prostate cancer. Clin Cancer Res 2005 ; 11 : 3854-61.
46. Tolcher AW. Phase I/II open-label study of YM155 plus docetaxel and prednisone in men with hormone refractory prostate cancer (HRPC). ASCO Genitourinary Cancers Symposium 2009 (Abstr 214).
47. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005 ; 12 : 634-43.
48. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004 ; 64 : 5036-43.
49. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T,Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004 ; 22 : 2108-21.
50. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009 ; 15 : 4799-805.
51. Tolcher AW. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009 ; 27: Abstr 3503.
52. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 ; 361 : 123-34.
53. Pacey SC. A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. J Clin Oncol 2009 ; 27 : Abstr 3534.
54. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, et al. Phase II, two-stage, single-armtrial of the histone deacetylase inhibitor (HDACi) romidepsin inmetastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2009 [Epub ahead of print].
55. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007 ; 13 : 5834-40.
56. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005 ; 23 : 455-60.
57. Gravis G, Bladou F, Salem N, Gonçalves A, Esterni B, Walz J, et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008 ; 19 : 1624-8.
58. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, et al. A phase II trial of docetaxel and erlotinib as firstline therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007 ; 7 : 142.
59. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999 ; 59 : 803-6.
60. Lara Jr PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004 ; 100 : 2125-31.
61. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000 ; 18 : 3894-903.
62. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase II trial. Prostate 2004 ; 60 : 197-204.
63. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006 ; 24 : 3089-94.
64. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007 ; 13 : 3883-91.
65. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006 ; 12 : 3394-401.
66. Kaufman HL, Wang W, Manola J, Dipaola RS, Ko YJ, Sweeney C, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004 ; 22 : 2122-32.
67. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999 ; 5 : 1738-44.
68. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007 ; 13 : 1810-5.
69. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled antiprostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004 ; 22 : 2522-31.
70. Camparo P, Vieillefond A. Molecular aspects of prostate cancer: recent data from the literature. Bull Cancer 2007 ; 94 : F77-F88 (Review French).
71. Albiges-Sauvin L, Lévy A, Massard C, Fizazi K. Prognosis and predictive factors in prostate cancer. Bull Cancer 2009 ; 96 : 439-49.